Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
22 Juin 2023 - 1:00PM
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage
immuno-oncology company, today announced that it will be added to
the broad-market Russell 3000® Index and small-cap Russell 2000® at
the conclusion of the 2023 Russell indexes annual reconstitution,
effective after the U.S. equity markets open on June 26, 2023
according to a preliminary list of additions.
Every year FTSE Russell conducts updates to its
various indexes based on total market capitalization and style
attributes. Membership in the U.S. all-cap Russell 3000 Index
remains in place for one year and means automatic inclusion in the
appropriate growth and value style indexes, which is the small-cap
Russell 2000 Index for Genelux. The 2023 index showed noteworthy
growth in the health care industry, with a majority of the
companies moving from small-cap to large-cap coming from the health
care space.
“Our inclusion in these Russell indexes is a
reflection of not just the market's recognition of our recent
clinical successes, but also the potential that lies within
Olvi-Vec” said Thomas Zindrick, President, CEO and Chairman of
Genelux. “Our inclusion among larger market cap companies should
help to increase investor awareness, expand institutional
ownership, and provide additional liquidity in our stock.”
For further information on the Russell 2000®
Index and the Russell indexes reconstitution, please find the
“Russell Reconstitution” section on the FTSE Russell
website.
About Genelux
CorporationGenelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic immunotherapies for patients suffering
from aggressive and/or difficult-to-treat solid tumor types. The
Company's most advanced product candidate, Olvi-Vec (olvimulogene
nanivacirepvec), is a proprietary, modified strain of the vaccinia
virus (VACV), a stable DNA virus with a large engineering capacity.
Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a
multi-center, randomized, open-label Phase 3 registrational trial
evaluating the efficacy and safety of Olvi-Vec in patients with
platinum-resistant/refractory ovarian cancer. The core of Genelux'
discovery and development efforts revolves around the company's
proprietary CHOICE™ platform from which the Company has developed
an extensive library of isolated and engineered oncolytic vaccinia
virus immunotherapeutic product candidates, including Olvi-Vec. For
more information, please visit www.genelux.com and follow us on
Twitter @Genelux_Corp and on LinkedIn.
About FTSE Russell:FTSE Russell
is a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell
calculates thousands of indexes that measure and benchmark markets
and asset classes in more than 70 countries, covering 98% of the
investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $20.1 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, exchange-traded fund (ETF) providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based
derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering.
FTSE Russell is wholly owned by London Stock
Exchange Group.
Forward-Looking StatementsThis
release contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
“Forward-looking statements” describe future expectations, plans,
results, or strategies and are generally preceded by words such as
“believes,” “anticipates,” “expect,” “may,” “plan” or “will”.
Forward-looking statements in this release include, but are not
limited to, statements related to Genelux being added to the
broad-market Russell 3000® Index and small-cap Russell 2000® at the
conclusion of the 2023 Russell indexes annual reconstitution, the
potential within Genelux’s oncolytic virus platform, and Genelux’s
inclusion among larger market cap companies helping to increase
investor awareness, expand institutional ownership, and provide
additional liquidity in Genelux’s stock. Such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events, or results to differ materially from
those projected in the forward-looking statements. These and other
risks are identified under the caption “Risk Factors” in Genelux’
filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date. Genelux
does not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLCgenelux@allelecomms.com815.721.4912
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024